A new approach to treat dry age-related macular degeneration
A Ribozyme Rescue Strategy for Dry Age-Related Macular Degeneration
This study is exploring a new treatment for dry age-related macular degeneration and juvenile macular degeneration by using special tools to help clear out harmful substances in the eye, with the hope of protecting and improving vision for those affected.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Western New York Healthcare System NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-11138540 on NIH RePORTER |
What this research studies
This research focuses on developing a novel therapeutic strategy to address dry age-related macular degeneration (dAMD) and juvenile macular degeneration (JMD) by targeting toxic substances that accumulate in the retina. The approach involves using ribozymes to potentially reduce the buildup of harmful compounds in retinal pigment epithelial cells, which are crucial for supporting vision. By investigating the biochemical processes that lead to cell damage and death in these conditions, the research aims to find a way to protect and restore retinal health. Patients may be monitored for changes in their retinal health and visual function as part of the treatment evaluation.
Who could benefit from this research
Good fit: Ideal candidates for this research are older adults experiencing symptoms of dry age-related macular degeneration or individuals with juvenile macular degeneration.
Not a fit: Patients with other forms of macular degeneration or those without retinal health issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow down or reverse vision loss in patients with dry age-related macular degeneration.
How similar studies have performed: While the specific ribozyme approach is novel, similar strategies targeting toxic retinal compounds have shown promise in other studies.
Where this research is happening
Buffalo, United States
- VA Western New York Healthcare System — Buffalo, United States (Active)
Researchers
- Principal investigator: Sullivan, John M. — VA Western New York Healthcare System
- Study coordinator: Sullivan, John M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.